Skip to main content
Fig. 1 | Journal of Experimental & Clinical Cancer Research

Fig. 1

From: miR-539 inhibits prostate cancer progression by directly targeting SPAG5

Fig. 1

SPAG5 is gradually increased in normal prostate, primary PCa, metastatic PCa, CRPC, and NEPC. a-e, Scatter plots represent SPAG5 mRNA in normal prostate and primary PCa samples; d-h, and i, Scatter plots represent SPAG5 mRNA in primary PCa and metastatic PCa samples; i, Scatter plots represent SPAG5 mRNA in metastatic PCa and CRPC samples; j. Scatter plots represent SPAG5 mRNA in prostate adernocarcinoma and NEPC samples; k, Scatter plots showed that SPAG5 mRNA was upregulated in three NEPC models (LTL331R, LTL352, and LTL370) relative to these prostate adenocarcinoma models, metastatic (LTL313H) PCa xenograft line relative to non-metastatic (LTL313B) PCa xenograft line, CRPC xenograft model (313BR) compared with LTL313B; l, Scatter plots showed that SPAG5 was downregulated after host castration and significantly upregulated in fully relapsed NEPC xenografts

Back to article page